



February 15, 2019 [CORRECTION: April 9, 2020]

Paul Schaeffer, FSA, MAAA  
Actuarial Senior Director  
Cigna Health and Life Insurance Company 900 Cottage  
Grove Road  
Bloomfield, CT 06002

Re: Cigna Health and Life Insurance Company  
Company NAIC # 67369; FEIN # 59-1031071  
VT - Cigna LG Major Medical Filing 2020  
SERFF Tracking # CCGP-132206853

Dear Mr. Schaeffer:

Lewis & Ellis, Inc (L&E) have been retained by the Green Mountain Care Board ("GMCB") to review the above referenced Large Group product filing submitted on 03/18/2020. Upon review of the actuarial memorandum and related information submitted, the following additional information is needed:

1. Regarding the response to question 2 of the previous objection letter – we note that the pharmacy rating methodology changes do not appear to be part of the three components of the requested rate increase.
  - a. If these changes are not included in any of the three components of the requested rate increase, please confirm that the pharmacy rating methodology changes are not expected to have an impact on rates.
  - b. If these changes are included in any of the three components of the requested rate increase, please explain where they are incorporated and provide the magnitude of the impact.
2. Regarding the response to question 3 of the previous objection letter – please complete the following table for the impact of the updated rating variables.

Factor Change	% Impact	Weight
Medical Area Factors		
Pharmacy Area Factors		
All Rating Variables	0.8%	100.0%

If the weights have changes from the 81.4% and 18.6% used in the previously approved filing, please explain the reason(s) for the difference(s).

3. Regarding the response to question 3 of the previous objection letter –

- a. Please provide the Medical Trend (6.1%) and Rx Trend (7.9%) breakout for utilization, unit cost, mix, etc.
  - b. Please reconcile the 6.1% Medical Trend to the trend in tables 4 (6.75%), 27 & 28 (7.26%, 7.96%, 6.87%) of the rating manual, and the pricing trend supplemental exhibit (“VT 2020 Supplemental Exhibits\_Hardcode.pdf”) & the response to question #7 of the previous objection letter (7.3% & 8.0%).
  - c. Please reconcile the 7.9% Rx Trend to the trend in tables 48 & 49 of the rating manual, the pharmacy trend supplemental exhibit (8.5% & 6.8%), and the response to question #7 of the previous objection letter (8.5% & 6.7%).
4. The 15.0% average requested rate increase ranges from -0.4% to 30.8%. What are the reason(s) for the rate increase range?
  5. The pricing trend supplemental exhibit (“VT 2020 Supplemental Exhibits\_Hardcode.pdf”) provide Vermont monthly medical claims experience and 3 years historical medical PMPM trends. Please provide a similar exhibit for pharmacy claims and PMPM trends.

Please respond as soon as possible, but no later than April 15, 2020.

Our review of filing will be placed in suspense pending your response. Contact me if you have any questions.

Sincerely,



Traci Hughes, ASA, MAAA  
Vice President & Consulting Actuary



**LEWIS & ELLIS, INC. – ACTUARIES AND CONSULTANTS**  
700 South Central Expy, Ste 550, Allen, TX 75013  
1-972-850-0850 [thughes@lewisellis.com](mailto:thughes@lewisellis.com)